中国疟疾研究与发展的国内趋势及其全球影响。

Domestic trends in malaria research and development in China and its global influence.

作者信息

Huang Yang-Mu, Shi Lu-Wen, She Rui, Bai Jing, Jiao Shi-Yong, Guo Yan

机构信息

School of Public Health, Peking University Health Science Center, Xueyuan Road 38, Haidian District, Beijing, 100191, China.

School of Pharmaceutical Science, Peking University Health Science Center, Xueyuan Road 38, Haidian District, Beijing, 100191, China.

出版信息

Infect Dis Poverty. 2017 Jan 10;6(1):4. doi: 10.1186/s40249-016-0222-x.

DOI:10.1186/s40249-016-0222-x

PMID:28069075

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5223349/

Abstract

BACKGROUND

Though many countries, including China, are moving towards malaria elimination, malaria remains a major global health threat. Due to the spread of antimalarial drug resistance and the need for innovative medical products during the elimination phase, further research and development (R&D) of innovative tools in both epidemic and elimination areas is needed. This study aims to identify the trends and gaps in malaria R&D in China, and aims to offer suggestions on how China can be more effectively involved in global malaria R&D.

METHODS

Quantitative analysis was carried out by collecting data on Chinese malaria-related research programmes between 1985 and 2014, invention patents in China from 1985 to 2014, and articles published by Chinese researchers in PubMed and Chinese databases from 2005 to 2014. All data were screened and extracted for numerical analysis and were categorized into basic sciences, drug/drug resistance, immunology/vaccines, or diagnostics/detection for chronological and subgroup comparisons.

RESULTS

The number of malaria R&D activities have shown a trend of increase during the past 30 years, however these activities have fluctuated within the past few years. During the past 10 years, R&D on drug/drug resistance accounted for the highest percentages of research programmes (32.4%), articles (55.0% in PubMed and 50.6% in Chinese databases) and patents (45.5%). However, these R&D activities were mainly related to artemisinin. R&D on immunology/vaccines has been a continuous interest for China's public entities, but the focus remains on basic science. R&D in the area of high-efficiency diagnostics has been rarely seen or reported in China.

CONCLUSIONS

China has long been devoted to malaria R&D in multiple areas, including drugs, drug resistance, immunology and vaccines. R&D on diagnostics has received significantly less attention, however, it should also be an area where China can make a contribution. More focus on malaria R&D is needed, especially in the area of diagnostics, if China would like to contribute in a more significant way to global malaria control and elimination.

摘要

背景

尽管包括中国在内的许多国家都在朝着消除疟疾的目标迈进，但疟疾仍然是全球主要的健康威胁。由于抗疟药物耐药性的传播以及在消除阶段对创新医疗产品的需求，在疟疾流行地区和消除地区都需要进一步开展创新工具的研发工作。本研究旨在确定中国疟疾研发的趋势和差距，并就中国如何更有效地参与全球疟疾研发提供建议。

方法

通过收集1985年至2014年中国疟疾相关研究项目的数据、1985年至2014年中国的发明专利，以及2005年至2014年中国研究人员在PubMed和中文数据库上发表的文章，进行定量分析。所有数据都经过筛选和提取，以进行数值分析，并按基础科学、药物/耐药性、免疫学/疫苗或诊断/检测进行分类，以便进行时间序列和亚组比较。

结果

在过去30年中，疟疾研发活动数量呈上升趋势，但在过去几年中有所波动。在过去10年中，药物/耐药性方面的研发在研究项目中占比最高（32.4%），在文章中占比也最高（在PubMed中占55.0%，在中文数据库中占50.6%），在专利中占比同样最高（45.5%）。然而，这些研发活动主要与青蒿素有关。免疫学/疫苗方面的研发一直是中国公共机构持续关注的领域，但重点仍在基础科学上。中国在高效诊断领域的研发很少见或鲜有报道。